{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:37:42Z","timestamp":1787024262201,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.2119\/molmed.2016.00124","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T03:18:00Z","timestamp":1475032680000},"page":"597-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Resveratrol Administration Increases Transthyretin Protein Levels, Ameliorating AD Features: The Importance of Transthyretin Tetrameric Stability"],"prefix":"10.1186","volume":"22","author":[{"given":"Lu\u00eds Miguel","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Alemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Costa","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alexandre","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"2201597_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN Murtagh FR. (1995) English translation of Alzheimer\u2019s 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde. Clin. Anat. 8:429\u201331","journal-title":"Clin. Anat."},{"key":"2201597_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K Arrighi HM. (2007) Forecasting the global burden of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 3:186\u201391.","journal-title":"Alzheimer\u2019s Dement."},{"key":"2201597_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","volume":"11","author":"Alzheimer\u2019s disease factsfigures","year":"2015","unstructured":"Alzheimer\u2019s disease facts and figures. (2015) Alzheimer\u2019s Dement. 11:332\u201384.","journal-title":"Alzheimer\u2019s Dement."},{"key":"2201597_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.biocel.2008.12.015","volume":"41","author":"SW Pimplikar","year":"2009","unstructured":"Pimplikar SW. (2009) Reassessing the amyloid cascade hypothesis of Alzheimer\u2019s disease. Int. J. Biochem. Cell Biol. 41:1261\u201368.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2201597_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, et al. (2000) Clearance of Alzheimer\u2019s amyloid-ss (1\u201340) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489\u201399.","journal-title":"J. Clin. Invest."},{"key":"2201597_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, et al. (2015) Clearance systems in the brain: implications for Alzheimer disease. Nat. Rev. Neurol. 11:457\u201370.","journal-title":"Nat. Rev. Neurol."},{"key":"2201597_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2045-8118-8-21","volume":"8","author":"CL Pascale","year":"2011","unstructured":"Pascale CL, et al. (2011) Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS. 8:21.","journal-title":"Fluids Barriers CNS."},{"key":"2201597_CR8","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1073\/pnas.91.18.8368","volume":"91","author":"AL Schwarzman","year":"1994","unstructured":"Schwarzman AL, et al. (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 91:8368\u201372.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2201597_CR9","first-page":"146","volume":"199","author":"AL Schwarzman","year":"1996","unstructured":"Schwarzman AL, Goldgaber D. (1996) Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found. Symp. 199:146\u201360; discussion 160\u201364.","journal-title":"Ciba Found. Symp."},{"key":"2201597_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/156720512803251057","volume":"9","author":"CA Ribeiro","year":"2012","unstructured":"Ribeiro CA, et al. (2012) Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. Curr. Alzheimer Res. 9:881\u201389.","journal-title":"Curr. Alzheimer Res."},{"key":"2201597_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/jnnp.63.4.506","volume":"63","author":"JM Serot","year":"1997","unstructured":"Serot JM, Christmann D, Dubost T, Couturier M. (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 63:506\u20138.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2201597_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0014-5793(98)00234-8","volume":"425","author":"A Merched","year":"1998","unstructured":"Merched A, et al. (1998) Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer\u2019s patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 425:225\u201328.","journal-title":"FEBS Lett."},{"key":"2201597_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-2008-14102","volume":"14","author":"SF Gloeckner","year":"2008","unstructured":"Gloeckner SF, et al. (2008) Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J. Alzheimer\u2019s Dis. 14:17\u201325.","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2201597_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, et al. (2015) Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener. 10:64.","journal-title":"Mol. Neurodegener."},{"key":"2201597_CR15","doi-asserted-by":"crossref","unstructured":"Choi SH, et al. (2007) Accelerated Abeta deposition in APPswe\/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J. Neurosci. 27P7006\u201310.","DOI":"10.1523\/JNEUROSCI.1919-07.2007"},{"key":"2201597_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/JAD-2011-110488","volume":"27","author":"SM Oliveira","year":"2011","unstructured":"Oliveira SM, Ribeiro CA, Cardoso I, Saraiva MJ. (2011) Gender-dependent transthyretin modulation of brain amyloid-\u03b2 levels: evidence from a mouse model of Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 27, 429\u201339.","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2201597_CR17","doi-asserted-by":"publisher","first-page":"20164","DOI":"10.1038\/srep20164","volume":"6","author":"M Alemi","year":"2016","unstructured":"Alemi M, et al. (2016) Transthyretin participates in beta-amyloid transport from the brain to the liver: involvement of the low-density lipoprotein receptor-related protein 1? Sci. Rep. 6:20164.","journal-title":"Sci. Rep."},{"key":"2201597_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.febslet.2008.02.034","volume":"582","author":"R Costa","year":"2008","unstructured":"Costa R, Gon\u00e7alves A, Saraiva MJ, Cardoso I. (2008) Transthyretin binding to A-Beta peptide: impact on A-Beta fibrillogenesis and toxicity. FEBS Lett. 582,:936\u201342.","journal-title":"FEBS Lett."},{"key":"2201597_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3233\/JAD-131355","volume":"39","author":"CA Ribeiro","year":"2014","unstructured":"Ribeiro CA, et al. (2014) Transthyretin stabilization by iododiflunisal promotes amyloid-\u03b2 peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer\u2019s disease mouse model. J. Alzheimer\u2019s Dis. 39:357\u201370.","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2201597_CR20","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1021\/bi101280t","volume":"49","author":"J Du","year":"2010","unstructured":"Du J, Murphy RM. (2010) Characterization of the interaction of \u03b2-amyloid with transthyretin monomers and tetramers. Biochemistry. 49: 8276\u201389.","journal-title":"Biochemistry"},{"issue":"50","key":"2201597_CR21","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1523\/JNEUROSCI.2561-13.2013","volume":"33","author":"X. Li","year":"2013","unstructured":"Li X, et al. Mechanisms of transthyretin inhibition of \u03b2-amyloid aggregation in vitro. J. Neurosci. 33:19423\u201333.","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"2201597_CR22","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.bbadis.2013.09.011","volume":"1832","author":"Roberta Cascella","year":"2013","unstructured":"Cascella R, et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim. Biophys. Acta \u2014 Mol. Basis Dis. 1832:2302\u201314.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2201597_CR23","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.1117799109","volume":"109","author":"B Mannini","year":"2012","unstructured":"Mannini B, et al. (2012) Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc. Natl. Acad. Sci. 109:12479\u201384.","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2201597_CR24","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/0140-6736(92)91277-F","volume":"339","author":"S Renaud","year":"1992","unstructured":"Renaud S, de Lorgeril M. (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339:1523\u201326.","journal-title":"Lancet"},{"key":"2201597_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1755-5949.2008.00045.x","volume":"14","author":"H Rocha-Gonz\u00e1lez","year":"2008","unstructured":"Rocha-Gonz\u00e1lez H, Ambriz-Tututi M, Granados-Soto V. (2008) Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neuroscience and Therapeutics. 14:234\u201347.","journal-title":"CNS Neuroscience and Therapeutics"},{"key":"2201597_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/138161212798919075","volume":"18","author":"F Li","year":"2012","unstructured":"Li F, Gong Q, Dong H, Shi J. (2012) Resveratrol, A Neuroprotective Supplement for Alzheimer\u2019s Disease. Curr. Pharm. Des. 18:27\u201333.","journal-title":"Curr. Pharm. Des."},{"key":"2201597_CR27","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","volume":"26","author":"D Kim","year":"2007","unstructured":"Kim D, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer\u2019s disease and amyotrophic lateral sclerosis. EMBO J. 26:3169\u201379.","journal-title":"EMBO J."},{"key":"2201597_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuint.2008.10.008","volume":"54","author":"SS Karuppagounder","year":"2009","unstructured":"Karuppagounder SS, et al. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer\u2019s disease. Neurochem. Int. 54:111\u201318.","journal-title":"Neurochem. Int."},{"key":"2201597_CR29","doi-asserted-by":"publisher","first-page":"37377","DOI":"10.1074\/jbc.M508246200","volume":"280","author":"P Marambaud","year":"2005","unstructured":"Marambaud P, Zhao H, Davies P. (2005) Resveratrol promotes clearance of Alzheimer\u2019s disease amyloid-beta peptides. J. Biol. Chem. 280:37377\u201382.","journal-title":"J. Biol. Chem."},{"key":"2201597_CR30","first-page":"1","volume":"7486","author":"B Varamini","year":"2013","unstructured":"Varamini B, Sikalidis AK, Bradford KL. (2013) Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. Int. J. Food Sci. Nutr. 7486:1\u20138.","journal-title":"Int. J. Food Sci. Nutr."},{"key":"2201597_CR31","doi-asserted-by":"publisher","first-page":"e45368","DOI":"10.1371\/journal.pone.0045368","volume":"7","author":"CA Ribeiro","year":"2012","unstructured":"Ribeiro CA, Saraiva MJ, Cardoso I. (2012) Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide: Relevance in Alzheimer\u2019s Disease. PLoS One. 7 e45368.","journal-title":"PLoS One."},{"key":"2201597_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/74082","volume":"7","author":"T Klabunde","year":"2000","unstructured":"Klabunde T, et al. (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 7:312\u201321.","journal-title":"Nat. Struct. Biol."},{"issue":"50","key":"2201597_CR33","doi-asserted-by":"publisher","first-page":"29769","DOI":"10.1074\/jbc.M115.690172","volume":"290","author":"Paola Florio","year":"2015","unstructured":"Florio P, et al. Transthyretin binding heterogeneity and antiamyloidogenic activity of natural polyphenols and their metabolites. J. Biol. Chem. 290:29769\u201380.","journal-title":"Journal of Biological Chemistry"},{"key":"2201597_CR34","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1021\/bi00223a017","volume":"30","author":"H Furuya","year":"1991","unstructured":"Furuya H, et al. (1991) Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry. 30:2415\u201321.","journal-title":"Biochemistry"},{"key":"2201597_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF02820508","volume":"6","author":"MR Almeida","year":"1997","unstructured":"Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ. (1997) Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine. 6:309\u201315.","journal-title":"Endocrine"},{"key":"2201597_CR36","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1073\/pnas.90.6.2375","volume":"90","author":"V Episkopou","year":"1993","unstructured":"Episkopou V, et al. (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc. Natl. Acad. Sci. U.S.A. 90:2375\u201379.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2201597_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/archneur.65.7.906","volume":"65","author":"JR Steinerman","year":"2008","unstructured":"Steinerman JR, et al. (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 65:906\u201312.","journal-title":"Arch. Neurol."},{"key":"2201597_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0009-9120(98)00027-7","volume":"31","author":"S Kunicki","year":"1998","unstructured":"Kunicki S, Richardson J, Mehta PD, Kim KS, Zorychta E. (1998) The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin. Biochem. 31:409\u201315.","journal-title":"Clin. Biochem."},{"key":"2201597_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","volume":"1215","author":"T Walle","year":"2011","unstructured":"Walle T. (2011) Bioavailability of resveratrol. Ann. N.Y. Acad. Sci. 1215:9\u201315.","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2201597_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/molecules15031196","volume":"15","author":"EL Robb","year":"2010","unstructured":"Robb EL, Stuart JA. (2010) Trans-resveratrol as a neuroprotectant. Molecules. 15:1196\u2013212.","journal-title":"Molecules"},{"key":"2201597_CR41","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1158\/0008-5472.CAN-10-2027","volume":"70","author":"KR Patel","year":"2010","unstructured":"Patel KR, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70:7392\u201399.","journal-title":"Cancer Res."},{"key":"2201597_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","volume":"410","author":"S Bourgault","year":"2011","unstructured":"Bourgault S, et al. (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res Commun. 410:707\u201313.","journal-title":"Biochem. Biophys. Res Commun."},{"key":"2201597_CR43","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.febslet.2015.02.020","volume":"589","author":"Y Mu","year":"2015","unstructured":"Mu Y, et al. (2015) CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci. FEBS Lett. 589:849\u201356.","journal-title":"FEBS Lett."},{"key":"2201597_CR44","unstructured":"Blake CCF, Geisow MJ, Swan IDA, Rerat C, Rerat B. (1974) Structure of human plasma prealbumin at 2.5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J. Mol. Biol. 88."},{"issue":"3","key":"2201597_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","volume":"121","author":"C.C.F. Blake","year":"1978","unstructured":"Blake CC, Geisow MJ, Oatley SJ, R\u00e9rat B, R\u00e9rat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J. Mol. Biol. 121:339\u201356.","journal-title":"Journal of Molecular Biology"},{"key":"2201597_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1021\/bi00673a014","volume":"14","author":"RN Ferguson","year":"1975","unstructured":"Ferguson RN, Edelhoch H, Saroff HA, Robbins J, Cahnmann HJ. (1975) Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid. Biochemistry. 14:282\u201389.","journal-title":"Biochemistry"},{"key":"2201597_CR47","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/jn\/131.6.1844","volume":"131","author":"Y Kimura","year":"2001","unstructured":"Kimura Y, Okuda H. (2001) Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor induced neovascularization in Lewis lung carcinoma bearing mice. J. Nutr. 131:1844\u201349.","journal-title":"J. Nutr."},{"key":"2201597_CR48","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1196\/annals.1395.059","volume":"1100","author":"J Gruber","year":"2007","unstructured":"Gruber J, Soon YT, Halliwell B. (2007) Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. In: Ann. N.Y. Acad. Sci. 1100:530\u201342.","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2201597_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/mp.2008.96","volume":"14","author":"KA Bates","year":"2009","unstructured":"Bates KA, et al. (2009) Clearance mechanisms of Alzheimer\u2019s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry. 14:469\u201386.","journal-title":"Mol. Psychiatry."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2016.00124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2016.00124\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2016.00124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2016.00124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T01:37:33Z","timestamp":1554514653000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2016.00124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2201597"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2016.00124","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"9 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}